MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462833 | Name: Methylprednisolone suleptanate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Methylprednisolone suleptanate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. It acts as a prodrug of methylprednisolone. Methylprednisolone suleptanate was developed as an improved alternative to methylprednisolone acetate with greater water solubility for use by intravenous administration.

Chemical Structure

Methylprednisolone suleptanate
Methylprednisolone suleptanate
CAS#90350-40-6

Theoretical Analysis

MedKoo Cat#: 462833

Name: Methylprednisolone suleptanate

CAS#: 90350-40-6

Chemical Formula: C33H48NNaO10S

Exact Mass: 673.2897

Molecular Weight: 673.79

Elemental Analysis: C, 58.83; H, 7.18; N, 2.08; Na, 3.41; O, 23.74; S, 4.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Medrosol; Promedrol; U 67590A;
IUPAC/Chemical Name
sodium 2-(8-(2-((6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-N-methyl-8-oxooctanamido)ethane-1-sulfonate
InChi Key
CDMLLMOLWUKNEK-AOHDELFNSA-M
InChi Code
InChI=1S/C33H49NO10S.Na/c1-21-17-23-24-12-14-33(40,32(24,3)19-26(36)30(23)31(2)13-11-22(35)18-25(21)31)27(37)20-44-29(39)10-8-6-5-7-9-28(38)34(4)15-16-45(41,42)43;/h11,13,18,21,23-24,26,30,36,40H,5-10,12,14-17,19-20H2,1-4H3,(H,41,42,43);/q;+1/p-1/t21-,23-,24-,26-,30+,31-,32-,33-;/m0./s1
SMILES Code
C[C@H]1C[C@H]2[C@@H]3CC[C@](C(COC(CCCCCCC(N(CCS(=O)([O-])=O)C)=O)=O)=O)([C@]3(C[C@@H]([C@@H]2[C@]4(C=CC(C=C14)=O)C)O)C)O.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 673.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ferry JJ, Della-Coletta AA, Weber DJ, VanderLugt JT. Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. J Clin Pharmacol. 1994 Nov;34(11):1109-15. doi: 10.1002/j.1552-4604.1994.tb01988.x. PMID: 7876403. 2: Paggiaro P. Methylprednisolone suleptanate Pharmacia Corp. Curr Opin Investig Drugs. 2000 Sep;1(1):97-103. PMID: 11249603. 3: Muir JF, Godard PH, Verhaert, Leophonte P, Racineux JL, Harry JD. Seventy-two hour comparison of methylprednisolone suleptanate and methylprednisolone sodium succinate in patients with acute asthma. Br J Clin Pract. 1996 Dec;50(8):440-5. PMID: 9039715. 4: Parker TJ, Daley-Yates PT, Wood SA. A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Br J Clin Pharmacol. 1997 Jun;43(6):589-92. doi: 10.1046/j.1365-2125.1997.00599.x. PMID: 9205818; PMCID: PMC2042787. 5: Daley-Yates PT, Gregory AJ, Brooks CD. Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Br J Clin Pharmacol. 1997 Jun;43(6):593-601. doi: 10.1046/j.1365-2125.1997.00598.x. PMID: 9205819; PMCID: PMC2042793. 6: Hashimoto M, Shinozaki Y, Katori M. Immediate inhibitory effect of methylprednisolone suleptanate (U-67590A) on antigen-induced cutaneous and airway anaphylactic responses in guinea-pigs. Br J Pharmacol. 1993 Mar;108(3):604-12. doi: 10.1111/j.1476-5381.1993.tb12849.x. PMID: 7682130; PMCID: PMC1908031. 7: Hall ED, Yonkers PA. Comparison of two ester prodrugs of methylprednisolone on early neurologic recovery in a murine closed head injury model. J Neurotrauma. 1989 Fall;6(3):163-8. doi: 10.1089/neu.1989.6.163. PMID: 2681792. 8: Ogata M, Noro Y, Yamada M, Tahara T, Nishimura T. Photodegradation products of methylprednisolone suleptanate in aqueous solution--evidence of a bicyclo[3.1.0]hex-3-en-2-one intermediate. J Pharm Sci. 1998 Jan;87(1):91-5. doi: 10.1021/js9701115. PMID: 9452975. 9: Nomura S, Harasawa Y, Hayashi S. Antishock effect of U-67,590A, methylprednisolone suleptanate, associated with restoration of lowered vascular reactivity in endotoxemic rats. J Cardiovasc Pharmacol. 1993 Oct;22(4):550-6. doi: 10.1097/00005344-199310000-00007. PMID: 7505356. 10: Taniguchi H, Nagamatsu T, Kojima R, Ito M, Suzuki Y. Marked antinephritic action and less adverse effects of methylprednisolone suleptanate by intermittent administration in rats. Jpn J Pharmacol. 1994 Feb;64(2):79-88. doi: 10.1254/jjp.64.79. PMID: 8028233. 11: Nomura Y, Hashimoto M, Hayashi S. Inhibitory effect of methylprednisolone suleptanate (U-67590A) on anaphylactic bronchoconstriction in guinea pigs. Res Commun Chem Pathol Pharmacol. 1992 Mar;75(3):275-90. PMID: 1509198. 12: Ichikawa Y, Hashimoto H, Kashiwazaki S, Kondo H, Akizuki M, Tokanou Y. [Methylprednisolone pulse therapy for SLE patients with CNS disorder]. Ryumachi. 1994 Aug;34(4):733-43. Japanese. PMID: 7974024. 13: Okamoto H, Mori K, Ohtsuka K, Ohuchi H, Ishii H. Effect of ionic strength on solution stability of PNU-67590A, a micellar prodrug of methylprednisolone. Pharm Res. 1997 Sep;14(9):1181-5. doi: 10.1023/a:1012150722729. PMID: 9327445. 14: Richards IM, Shields SK, Bienkowski MJ, Dunn CJ, Jacobsen EJ. Novel inhibitors of pulmonary eosinophil accumulation. Agents Actions Suppl. 1991;34:359-68. PMID: 1665309. 15: Shah JA, Weber DJ, Bothwell BE. High-performance liquid chromatographic determination of methylprednisolone and methylprednisolone 21-[8-[methyl-(2-sulfoethyl)amino]-8-oxoctanoate] sodium salt in human plasma. J Chromatogr. 1987 Feb 20;414(1):1-10. doi: 10.1016/0378-4347(87)80018-x. PMID: 3571374. 16: Shah JA, Weber DJ. Simultaneous determination of methylprednisolone and methylprednisolone 21-[8-[methyl-(2-sulfoethyl)amino]-8-oxooctanoate] sodium salt in human urine by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1989 Nov 24;496(2):245-54. doi: 10.1016/s0378-4347(00)82574-8. PMID: 2515202. 17: Cui Y, Tinker A, Clapp LH. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A. Br J Pharmacol. 2003 May;139(1):122-8. doi: 10.1038/sj.bjp.0705228. PMID: 12746230; PMCID: PMC1573826.